ABSTRACT BACKGROUND Symptoms and survival of patients with carcinoid syndrome have improved, but development of
These treatments have improved symptoms and longevity in patients with carcinoid syndrome (1-7); however, for patients with cardiac involvement, right-sided heart failure worsens their quality of life and leads to excess mortality. Valve surgery is the only effective treatment option for patients with symptomatic carcinoid heart disease (CaHD) and improves survival (8) . Without operation, only 10% of patients survive 2 years after the onset of New York Heart Association (NYHA) functional class III or IV symptoms (9) .
In this study, we evaluated short-term and long- SURGICAL MANAGEMENT. Treatment was not randomized. Initially, mechanical prostheses were recommended for tricuspid valve replacement because of the reported carcinoid involvement of a porcine bioprosthesis (13) . Over time, bioprostheses were increasingly used in patients considered to be at high risk for anticoagulation-related complications; because of the generally favorable short-term outcomes in these patients, bioprostheses were used more frequently.
Pulmonary valve intervention was performed if pulmonary valve disease was present. In our early experience, pulmonary valvectomy was preferred.
Subsequently, long-standing severe pulmonary valve regurgitation that occurred after this procedure was recognized to adversely affect right ventricular remodeling. Since 2002, the pulmonary valve has been routinely replaced when involved by CaHD (14) .
Meticulous pre-operative planning and perioperative care were instituted for patients with CaHD to prevent life-threatening carcinoid crises (15) or to institute early therapy should a crisis occur intraoperatively. Anesthetic management aimed to limit hemodynamic perturbations associated with carcinoid reactions, primarily through the use of intravenous octreotide and vasopressors, as well as to initiate aggressive therapy for long-standing right-sided heart failure with hemofiltration and diuresis (15) (16) (17) .
Intravenous octreotide acetate was used if flushing, unexplained hemodynamic lability, or volume loss occurred during extracorporeal circulation (17) . Simultaneous coronary artery bypass surgery 22 (11) Octreotide dose during operation, mg 0.5 (0.0-2.1) Pacemaker 11 (6) Time in hospital, days 9 AE 7
Death in hospital or within 30 days 20 (10) Values are mean AE SD (range), n (%), or median (range).
ASD ¼ atrial septal defect; CPB ¼ cardiopulmonary bypass; PFO ¼ patent foramen ovale.
Surgical Treatment Outcomes in Carcinoid Heart Disease median octreotide dose administered during the perioperative period was 0.5 mg (range 0 to 2.1 mg).
The overall mean hospital stay was 9 AE 7 days. and right-sided heart size and function ( Table 3) . Kaplan-Meier overall survival. Mechanical valve prostheses were used for tricuspid valve replacement in our early experience because of the reported carcinoid involvement of a porcine bioprosthesis (13) . Over time, we used bioprostheses more often in patients considered to be at higher than normal risk for anticoagulation-related complications; the generally favorable short-term outcome in these patients led us to use bioprostheses more liberally.
In addition, pathological review of explanted bioprostheses suggested that carcinoid involvement was an uncommon reason for valve dysfunction requiring reoperation; it was found in only 1 explanted bioprosthesis in our series.
The most frequent cause of tricuspid bioprosthesis dysfunction in our patients was thrombus. (14) . Homografts were used to replace the pulmonary valve early in our experience; however, in several patients, we identified premature dysfunction related to constriction of the homograft.
We now favor placement of a large stented bioprosthesis, facilitated with patch enlargement of the pulmonary valve annulus and outflow tract. Rarely, a mechanical prosthesis is used for tricuspid valve replacement (26) . In this setting when pulmonary valve replacement is indicated, a mechanical pulmonary prosthesis is preferred over bioprosthesis (28) . 30-day cardiac surgical mortality attributable to carcinoid heart disease according to era of operation.
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COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Valve replacement surgery should be considered for patients with symptomatic carcinoid heart disease before they develop advanced right-sided heart failure.
TRANSLATIONAL OUTLOOK: Future studies should seek to define imaging and biomarker strategies to distinguish rightsided heart failure from end-stage metastatic carcinoid disease and to guide timing of valve replacement surgery. Surgical Treatment Outcomes in Carcinoid Heart Disease
